An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males

British Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2010, Pages 645-655

  Oh, Chad K ^a   Faggioni, Raffaella ^a   Jin, Feng ^a   Roskos, Lorin K ^a   Wang, Bing ^a   Birrell, Claire ^a   Wilson, Rosamund ^b   Molfino, Nestor A ^a  

^a MEDIMMUNE   (United States)

^b Granary House   (United Kingdom)

Author keywords

Antibody; Asthma; Bioavailability; CAT 354; Half life; IL 13

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 13 ANTIBODY;

ADULT; ARTICLE; BACKACHE; BODY TEMPERATURE; BREAST TENDERNESS; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPISTAXIS; HEADACHE; HUMAN; IMMUNOGENICITY; JOINT SWELLING; LABORATORY TEST; MALE; MELANOCYTIC NEVUS; NORMAL HUMAN; NOSE CONGESTION; OCULAR PRURITUS; OPEN STUDY; POSTTRAUMATIC PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETICULOENDOTHELIAL SYSTEM; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SINUS CONGESTION; SINUS HEADACHE; SNEEZING; SORE THROAT; STEADY STATE; SUNBURN; TREATMENT DURATION; VITAL SIGN;

ADULT; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77952022559     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03647.x     Document Type: Article

References (24)

1. Bateman ED, Boshey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Perdersen SE GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004 170 : 836 844. (Pubitemid 39346477)
2. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 316. (Pubitemid 40293346)
3. Brightling CE, Symon FA, Birring SS, Bradding P, Pavord ID, Wardlaw AJ. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2002 110 : 899 905. (Pubitemid 36005878)
4. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992 326 : 298 304.
5. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003 111 : 677 690.
6. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998 282 : 2258 2261. (Pubitemid 29004074)
7. Berry MA, Parker D, Neale N, Woodman L, Morgan A, Monk P, Bradding P, Wardlaw AJ, Pavord ID, Brightling CE. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004 114 : 1106 1109. (Pubitemid 39469151)
8. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, Monk P, Bradding P, Wardlaw AJ, Pavord ID, Brightling CE. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008 121 : 685 691. (Pubitemid 351323866)
9. Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, Bradding P. Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003 33 : 1711 1716. (Pubitemid 38005392)
10. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998 282 : 2261 2263. (Pubitemid 29004075)
11. Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, Foster PS, Rothenberg ME. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001 108 : 594 601. (Pubitemid 32978032)
12. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999 103 : 779 788. (Pubitemid 29152623)
13. Mattes J, Yang M, Mahalingam S, Kuehr J, Webb DC, Simson L, Hogan SP, Koskinen A, McKenzie AN, Dent LA, Rothenberg ME, Matthaei KI, Young IG, Foster PS. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002 195 : 1433 1444. (Pubitemid 34602820)
14. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005 35 : 1096 1103. (Pubitemid 41603145)
15. Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R, Bradding P, Brightling CE. Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 2006 61 : 1047 1053. (Pubitemid 44177415)
16. Bhowmick B, Singh D, Molfino NA, Cranmer H, Birrell C, Faggioni R. A double-blind placebo controlled study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT-354, a recombinant human anti-IL13 antibody in subjects with moderate asthma Abstract No. 3021]. European Respiratory Society Annual Congress 2008.
17. Klakamp SL, Lu H, Tabrizi M, Funelas C, Roskos LK, Coleman D. Application of analytical detection concepts to immunogenicity testing. Anal Chem 2007 79 : 8176 8184. (Pubitemid 350060015)
18. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004 289 : 1 16. (Pubitemid 38900899)
19. Blease K. Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs 2008 9 : 1180 1184.
20. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008 8 : 477 483.
21. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006 11 : 81 8.
22. McLennan DN, Porter CJ, Edwards GA, Brumm M, Martin SW, Charman SA. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm Res 2003 20 : 1156 1162. (Pubitemid 36951839)
23. McLennan DN, Porter CJ, Edwards GA, Heatherington AC, Martin SW, Charman SA. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharm Res 2006 23 : 2060 2066.
24. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 2001 28 : 321 342. (Pubitemid 32953509)